logo
Plus   Neg
Share
Email

Lockheed Martin Boosts FY20 Net Sales Outlook - Quick Facts

While reporting financial results for the fourth quarter on Tuesday, Lockheed Martin Corp. (LMT) initiated earnings outlook for the full-year 2020, while boosting annual net sales outlook.

For fiscal 2020, the company now expects earnings in a range of $23.65 to $23.95 per share. Net sales are now projected to be between $62.75 billion and $64.25 billion, up from the prior forecast of about $62.0 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $24.29 per share on net sales of $62.55 billion for the year. Analysts' estimates typically exclude special items.

The company said its financial outlook for 2020 does not include potential impacts to its programs, including the F-35 program, resulting from U.S. Government actions related to Turkey. Currently, it does not expect this event will have a material impact on its 2020 financial results.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Novacyt S.A. said it is seeing unprecedented demand for the novel coronavirus or COVID-19 diagnostic test kit developed by Primerdesign, the company's molecular diagnostics division based in the UK. As of March 27, Primerdesign has sold and received orders for more than 17.8 million pounds of its CE-Mark COVID-19 tests. Novacyt is currently selling its COVID-19 test to more than 80 countries. The U.S. Food and Drug Administration has issued an Emergency Use Authorization to allow anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile as possible treatments for coronavirus (COVID-19) patients. This is the first EUA for a drug related to the COVID-19 response. Gilead Sciences Inc. said it is transitioning to "expanded access programs" from "compassionate use" programs for its experimental anti-coronavirus drug, remdesivir. The company noted that the expanded access will allow hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at one time, as they struggle to deal with the COVID-19 or coronavirus pandemic.
Follow RTT
>